|
|
|
|
| LEADER |
01456nam a2200349 u 4500 |
| 001 |
EB001999859 |
| 003 |
EBX01000000000000001162760 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Weir, Arielle
|
| 245 |
0 |
0 |
|a Epinephrine auto-Injectors for anaphylaxis
|h Elektronische Ressource
|b a review of the clinical effectiveness, cost-effectiveness, and guidelines
|c Arielle Weir, Charlene Argáez
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, April 24, 2020
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Injections, Intramuscular
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Anaphylaxis / drug therapy
|
| 653 |
|
|
|a Epinephrine / administration & dosage
|
| 653 |
|
|
|a Epinephrine / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Self Administration
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK563019
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|